Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.933 USD | +2.52% | -2.12% | -33.03% |
May. 09 | Oppenheimer Adjusts Seres Therapeutics Price Target to $4 From $5, Maintains Outperform Rating | MT |
May. 09 | Chardan Adjusts Price Target on Seres Therapeutics to $6 From $8, Keeps Buy Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-33.03% | 138M | |
+9.93% | 114B | |
+12.48% | 107B | |
-3.67% | 22.22B | |
-0.67% | 21.28B | |
-4.64% | 18.8B | |
-7.08% | 17.51B | |
-39.36% | 17.17B | |
+6.14% | 14.14B | |
+33.11% | 12.2B |
- Stock Market
- Equities
- MCRB Stock
- News Seres Therapeutics, Inc.
- Transcript : Seres Therapeutics, Inc., Q4 2022 Earnings Call, Mar 07, 2023